Adding IBRANCE (palbociclib) to letrozole treatment for advanced or metastatic breast cancer improves progression-free survival rate. Read More »

The Phase III SIERRA clinical trial will test effectiveness of Iomab-B when used prior to bone marrow transplants. Read More »

Pfizer and IBM announced today a novel research partnership that will lead to the development of groundbreaking remote monitoring solutions focused on revolutionizing the care Parkinson’s patients receive. Read More »

The U.S. Food and Drug Administration (FDA) has approved Celltrion’s INFLECTRA (biosimilar infliximab) for all qualified indications of the reference product, Remicade (infliximab). Read More »

Pfizer has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has approved a new presentation of Prevenar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, absorbed]). Read More »

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Iomab-B, a radioimmunotherapeutic developed by Actinium Pharmaceuticals that is designed to aid patients with reverted and stubborn Acute Myeloid Leukemia (AML) so they can receive a Hematopoietic Stem Cell Transplant (HSCT). Read More »

Actinium Pharmaceuticals has announced that it has named Jennifer Liberi Director of Clinical Operations. Read More »

Pfizer and Bristol-Myers Squibb have released the 17 abstracts that the two companies will present at the American College of Cardiology’s 65th Annual Scientific Session (ACC.16) in Chicago on April 2-4. Read More »

Pfizer has announced that the European Medicines Agency (EMA) has accepted its Marketing Authorization Application (MAA) for XELJANZ (tofacitinib citrate) for review. Read More »

Pfizer has announced that it will be presenting new data based on the research of tofacitinib in ulcerative colitis (UC) and Crohn’s disease at the 11th Congress of ECCO, which is scheduled for March 16-19 in Amsterdam. Read More »

Pfizer today released its 2015 integrated annual review, which is an in-depth look at the company’s financial, social and environmental performance. Read More »

Pfizer recently published the results to its Phase 3 study of BeneFIX Coagulation Factor IX (recombinant) 100 IU/kg prophylaxis compared to on-demand treatment for patients with moderately severe or severe hemophilia B. Read More »

The U.S. Food and Drug Administration (FDA) recently approved a new indication for the Novartis drug, Afinitor (everolimus). Read More »

Actinium Pharmaceuticals announced this week that its choice for Clinical Research Organization (CRO) that will conduct its Phase 3 Iomab-B clinical trial is Medpace. Read More »

Acorda Therapeutics Inc. announced last week that the waiting period has expired for its tender offer for Biotie Therapies, according to an amendment to the Hart-Scott-Rodino Antitrust Improvement Act of 1976 (HSR). Read More »

Pfizer Inc. announced last week that the United States Food and Drug Administration (FDA) has approved the expanded use of the drug IBRANCE (palbociclib). Read More »

Bristol-Myers Squibb announced today that it has finalized the sale of its HIV R&D portfolio to ViiV Healthcare. Read More »

Actinium Pharmaceuticals announced this week that it will be sending personnel from clinical and business development to the annual BMT Tandem Meetings held by the Center for International Blood & Marrow Transplant Research (CIBMTR) and the American Society of Blood and Marrow Transplantation (ASBMT). Read More »

Pfizer has announced that an agreement has been reached by its subsidiary, Wyeth, to resolve claims that its practice in calculating Medicaid rebates violated the Federal Civil False Claims Act and other laws. Read More »

Sandoz, a company owned by Novartis, announced last week that it has procured the rights to develop and commercialize PF_06438179 (infliximab) from Pfizer. Read More »